Advancing research from University of Pennsylvania, Kira was formed three years ago and made its public debut yesterday with $46m in funding.
Kira Pharmaceuticals, a US-based biotechnology developer focused on immune-mediated diseases that is exploiting research from University of Pennsylvania, emerged from stealth yesterday with a total of $46m in funding.
The cash came from 6 Dimensions Capital, an investment firm co-founded by pharmaceutical group WuXi AppTec, and Sinopharm Capital, the corporate venturing arm of pharmaceutical firm Sinopharm, as well as VC firms Quan Capital and Qiming Venture Partners.
Quan Capital was identified as the lead investor by Kira and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
